192 related articles for article (PubMed ID: 21040141)
1. An open-label trial of rituximab (Rituxan®) in multifocal motor neuropathy.
Chaudhry V; Cornblath DR
J Peripher Nerv Syst; 2010 Sep; 15(3):196-201. PubMed ID: 21040141
[TBL] [Abstract][Full Text] [Related]
2. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial.
Gorson KC; Natarajan N; Ropper AH; Weinstein R
Muscle Nerve; 2007 Jan; 35(1):66-9. PubMed ID: 16967492
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous immunoglobulin therapy for multifocal motor neuropathy.
Eftimov F; Vermeulen M; de Haan RJ; van den Berg LH; van Schaik IN
J Peripher Nerv Syst; 2009 Jun; 14(2):93-100. PubMed ID: 19691531
[TBL] [Abstract][Full Text] [Related]
4. A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study.
Misbah SA; Baumann A; Fazio R; Dacci P; Schmidt DS; Burton J; Sturzenegger M
J Peripher Nerv Syst; 2011 Jun; 16(2):92-7. PubMed ID: 21692906
[TBL] [Abstract][Full Text] [Related]
5. A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy.
Hahn AF; Beydoun SR; Lawson V; ; Oh M; Empson VG; Leibl H; Ngo LY; Gelmont D; Koski CL
J Peripher Nerv Syst; 2013 Dec; 18(4):321-30. PubMed ID: 24725024
[TBL] [Abstract][Full Text] [Related]
6. [Multifocal motor neuropathy: a retrospective study of the response to high-dose intravenous immunoglobulin (IVIg) and current perspectives for diagnosis and treatment].
Léger JM; Viala K; Maisonobe T; Bouche P
Bull Acad Natl Med; 2007 Oct; 191(7):1395-407; discussion 1407-9. PubMed ID: 18447061
[TBL] [Abstract][Full Text] [Related]
7. Intravenous immunoglobulin for maintenance treatment of multifocal motor neuropathy: A multi-center, open-label, 52-week phase 3 trial.
Kuwabara S; Misawa S; Mori M; Iwai Y; Ochi K; Suzuki H; Nodera H; Tamaoka A; Iijima M; Toda T; Yoshikawa H; Kanda T; Sakamoto K; Kusunoki S; Sobue G; Kaji R;
J Peripher Nerv Syst; 2018 Jun; 23(2):115-119. PubMed ID: 29635876
[TBL] [Abstract][Full Text] [Related]
8. [Improvement of severe and intravenous immunoglobulin-dependent multifocal motor neuropathy with conduction block after long-term rituximab].
Michaud A; Delmont E; Jeandel PY; Desnuelle C
Rev Neurol (Paris); 2011 Dec; 167(12):916-20. PubMed ID: 21752414
[TBL] [Abstract][Full Text] [Related]
9. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy.
Dalakas MC; Rakocevic G; Salajegheh M; Dambrosia JM; Hahn AF; Raju R; McElroy B
Ann Neurol; 2009 Mar; 65(3):286-93. PubMed ID: 19334068
[TBL] [Abstract][Full Text] [Related]
10. Long-term therapy with high doses of subcutaneous immunoglobulin in multifocal motor neuropathy.
Harbo T; Andersen H; Jakobsen J
Neurology; 2010 Oct; 75(15):1377-80. PubMed ID: 20938030
[TBL] [Abstract][Full Text] [Related]
11. Nerve excitability changes after intravenous immunoglobulin infusions in multifocal motor neuropathy and chronic inflammatory demyelinating neuropathy.
Boërio D; Créange A; Hogrel JY; Guéguen A; Bertrand D; Lefaucheur JP
J Neurol Sci; 2010 May; 292(1-2):63-71. PubMed ID: 20219211
[TBL] [Abstract][Full Text] [Related]
12. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy.
Latov N; Deng C; Dalakas MC; Bril V; Donofrio P; Hanna K; Hartung HP; Hughes RA; Merkies IS; van Doorn PA;
Arch Neurol; 2010 Jul; 67(7):802-7. PubMed ID: 20457948
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effect of rituximab monotherapy in multifocal motor neuropathy.
Stieglbauer K; Topakian R; Hinterberger G; Aichner FT
Neuromuscul Disord; 2009 Jul; 19(7):473-5. PubMed ID: 19467601
[TBL] [Abstract][Full Text] [Related]
14. Understanding the consequences of chronic inflammatory demyelinating polyradiculoneuropathy from impairments to activity and participation restrictions and reduced quality of life: the ICE study.
Merkies IS; Hughes RA; Donofrio P; Bril V; Dalakas MC; Hanna K; Hartung HP; Latov N; van Doorn PA; Deng C;
J Peripher Nerv Syst; 2010 Sep; 15(3):208-15. PubMed ID: 21040143
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of intravenous immunoglobulin in multifocal motor neuropathy.
Leger JM; Vargas S; Lievens I
Ann N Y Acad Sci; 2007 Sep; 1110():248-55. PubMed ID: 17911439
[TBL] [Abstract][Full Text] [Related]
16. Treatment of immune-mediated, dysimmune neuropathies.
Finsterer J
Acta Neurol Scand; 2005 Aug; 112(2):115-25. PubMed ID: 16008538
[TBL] [Abstract][Full Text] [Related]
17. High-dose Ig VENA is well tolerated and efficacious in patients with multifocal motor neuropathy.
Nobile-Orazio E; Cocito D; Briani C; Plasmati R; Schenone A; Gallia F; Marjanovic I; Suffredini AL
Neurol Sci; 2017 May; 38(5):899-902. PubMed ID: 28144763
[TBL] [Abstract][Full Text] [Related]
18. Multifocal motor neuropathy: the diagnostic spectrum and response to treatment.
Slee M; Selvan A; Donaghy M
Neurology; 2007 Oct; 69(17):1680-7. PubMed ID: 17954783
[TBL] [Abstract][Full Text] [Related]
19. [Multifocal motor neuropathies with conduction block: long-term follow-up of ten patients treated with IVIg].
Cros D; Drake K
Rev Neurol (Paris); 2006 Jun; 162 Spec No 1():3S46-3S50. PubMed ID: 17075525
[TBL] [Abstract][Full Text] [Related]
20. Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg.
Rüegg SJ; Fuhr P; Steck AJ
Neurology; 2004 Dec; 63(11):2178-9. PubMed ID: 15596777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
